Efficacy of Cortical Stimulation in a Non-Human Primate Model of Cortical Ischemi

中风是成年人运动功能障碍的主要原因。中风后的运动恢复与大脑皮层的功能和结构可塑性有关，但往往是不完整的，并以长期的残余缺陷为特征。在U54提案（翻译研究合作计划）中与其他几个研究小组合作，将在非人类灵长类动物皮质缺血模型中开发并优化一种新的治疗方法，以增强神经可塑性和运动恢复。这种治疗方法被称为皮质刺激（CS），在康复训练过程中对未被梗死损伤的皮质区域进行低水平电刺激。在本提案（完整提案的项目3）中，将解决三个具体目标。在Aim 1中，将在灵长类动物中评估U54啮齿动物项目中优化的CS参数对治疗效果和效果持久性的验证。在Aim 2中，应用的最佳皮质位置

Stroke is a leading cause of motor dysfunction in the adult population. Motor recovery from stroke is associated with functional and structural plasticity in the cerebral cortex, but is often incomplete and characterized by long-term residual deficits. In collaboration with several other investigative teams included in this U54 proposal (Cooperative Program in Translation Research), a new therapeutic approach to enhancing neuroplasticity and motor recovery will be developed and optimized in a nonhuman primate model of cortical ischemia. This therapy approach, termed Cortical Stimulation (CS), utilizes low-level electrical stimulation over cortical regions undamaged by the infarct, applied during rehabilitative training procedures. In this proposal (Project 3 of the full proposal), three specific aims will be addressed. In Aim 1, the verification of the efficacy of treatment and the persistence of effect using CS parameters optimized in U54 rodent projects will be evaluated in primates. In Aim 2, the optimal cortical location over which to apply stimulation will be evaluated. Therapy will compare the efficacy of stimulation over peri-infarct primary motor cortex with stimulation over the intact ventral premotor cortex ipsilateral to the infarct. In Aim 3, the efficacy of therapy initiated in the chronic post-infarct condition will be evaluated and compared to the efficacy of therapy initiated in the subacute condition. Location of stimulation will be determined by the results of Aim 2. Taken together, these three aims will provide a better understanding of the optimal parameters for promoting behavioral recovery from stroke-induced motor deficits in nonhuman primates. In collaboration with clinical investigative teams associated with this U54 proposal, it is hoped that the insights acquired from this animal model can be translated into improvements in treatment methods for human patients during clinical trials.